Fresh analysis suggests that people who come off blockbuster GLP-1 drugs like Wegovy and Mounjaro tend to recover shed pounds much more quickly than those who halt traditional diet and exercise programs.
Published data in a leading medical journal shows that while obese people often shed substantial amounts of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.
"People buying such medications should be informed of the potential of rapid rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a reversion to pre-treatment mass within about one and a half years.
Comparing Approaches
The research, which looked at dozens of studies involving thousands of participants, contrasted the outcomes of these new drugs with older methods.
The team note that individuals who shed pounds through diet and exercise typically experience a more gradual creep back—approximately 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Experts believe the mechanism of the drugs explains the amplified rebound.
The injections copy a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 levels far above than normal could lead to the system to produce less of its own natural hormone, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' results in appetite is unsuppressed, making binge eating a significant risk."
A Lifelong Condition?
Health authorities recommend the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts say that, due to the likelihood of weight regain, the treatment is often ongoing.
This opinion is echoed by pharmaceutical companies, who state that the findings "emphasize the chronic nature of obesity," akin to managing conditions like hypertension.
User Experiences
Individuals who have stopped the medication explain a intense resurgence of appetite.
"I experienced a switch that goes on and I was suddenly extremely hungry," said a patient.
This challenge is worsened if patients have not developed lasting lifestyle or habit modifications during treatment.
Significant Use
Figures show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is higher among females compared to males.
- The 40s and 50s age group shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
Ultimately, experts emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent fix and long-term success hinges on combined behavioural changes.
